FHL1 and cancer: Baseline antibody reactivity to several candidate autoantigens (FHL1, VTN, NEFL, EEF1A1, TUBB, TUBB4B, KNG1, ITLN1) previously reported autoantibody targets in melanoma, cancer, and autoimmune diseases31, 33 was significantly increased in the “no toxicity” patient cohort compared with the “high toxicity” and “all toxicity” groups (figure 3B,C).